A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ProVent
- Sponsors Dendreon Corporation
Most Recent Events
- 08 Oct 2024 Status changed from active, no longer recruiting to completed.
- 18 Oct 2023 Planned End Date changed from 1 May 2023 to 28 Feb 2024.
- 18 Oct 2023 Planned primary completion date changed from 1 May 2023 to 31 Dec 2023.